Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
